Benefits
Neuraminidase inhibition (anti-influenza mechanism)
In an in-vitro enzyme assay, Isenolic 8% reduced neuraminidase activity by up to 64% — a laboratory measurement in cell-free/cell-culture conditions, not a clinical outcome in people. Neuraminidase disassembles new flu virions from infected host cells, allowing them to spread to new cells. Inhibiting it prevents virus liberation and subsequent proliferation. These are in-vitro enzyme-assay findings only and do not establish that Isenolic treats or prevents influenza in people; it is not a substitute for prescribed antiviral medication.
Dose-dependent anti-influenza activity
Isenolic® showed dose-dependent anti-influenza activity in vitro, with IC50 values of 65.5 µg/ml (8% formulation) and 171.4 µg/ml (4% formulation) for influenza virus inhibition. The 8% formulation was approximately 2.6× more potent than the 4% formulation in these cell-culture assays. These are in-vitro potency comparisons and do not establish clinical benefit for symptom relief or prevention in people.
Cell viability protection during infection
Pre-treatment with 8% Isenolic at 100 µg/ml preserved 72.9% cell viability post-influenza infection in MDCK-SIAT1 cells (a standard in vitro flu infection model). This is an in-vitro cell-model finding only; it has not been shown to translate into prevention of infection or reduced viral spread in people.
Multi-target antiviral mechanism
In laboratory (in vitro) studies, ELA has been reported to penetrate cells and interfere with the entry of specific viruses. These are preclinical mechanistic observations and have not been shown to produce an antiviral benefit, or any advantage over antiviral drugs, in humans.
Antioxidant and immune support
Several studies report ELA provides antioxidant effects, promoting broader immunity beyond direct antiviral activity. Olive leaves have been related to multiple positive effects on the immune system, particularly against microbial threats. Reinforces the broader 'support immune system during respiratory illness season' positioning alongside the acute symptomatic use.
Traditional medicinal precedent
Olive leaf has been used for medicinal purposes since ancient Egypt — for fever combat and cold treatment. Ancient Greek culture also used olive leaf to lower fever. The long traditional use combined with modern characterized mechanisms (neuraminidase inhibition, multi-target antiviral activity) supports Isenolic's positioning as both traditionally validated and scientifically substantiated.
Sustainable and locally sourced
Pharmactive sources Isenolic from olive leaves locally in Spain — where olive cultivation has thousands of years of history. The extraction uses a patented, environmentally sound method that preserves extract quality while reducing waste. The local sourcing also supports traceability and quality control vs international supply chains where olive leaf extract adulteration is common.
Mechanism of action
Viral neuraminidase enzyme inhibition
Neuraminidase is a key enzyme on the surface of the influenza virus that disassembles new virions from infected host cells, allowing them to spread. In in-vitro assays, elenolic acid inhibits this enzyme. This is a laboratory mechanistic finding and does not by itself establish a clinical antiviral effect in people.
Direct cellular entry blockade
Elenolic acid directly penetrates host cells and blocks the entry of specific viruses at the receptor-binding step. This mechanism prevents infection before it establishes, complementing the neuraminidase inhibition that limits spread of already-infected cells. These mechanisms are described from in-vitro studies and have not been shown to make Isenolic effective for prevention or treatment of infection in humans.
Antimicrobial spectrum
Olive tree extracts have been documented sources of antimicrobial activity across viral, bacterial, and fungal pathogens since antiquity. Modern research has confirmed broad-spectrum activity. The mechanism supports Isenolic's positioning beyond influenza to broader respiratory tract infections, though influenza is the best-characterized indication.
Antioxidant ROS scavenging
ELA and other olive leaf phenolic compounds have direct antioxidant activity, scavenging reactive oxygen species (ROS) generated during viral infections. ROS contribute to inflammation and tissue damage during respiratory illness — antioxidant activity supports symptom reduction beyond pure antiviral mechanisms.
Clinical trials
In vitro comparison of Isenolic® (4% and 8% ELA formulations) vs oseltamivir (Tamiflu®) for anti-influenza activity. Tests included HPLC-MS characterization, cytotoxicity, viral neuraminidase inhibitor activity, and cell viability protection against influenza infection in MDCK-SIAT1 (sialic acid overexpressing Madin-Darby Canine Kidney) cells. Published 2021 (PMID 34839747).
Not applicable — in vitro study using MDCK-SIAT1 cell line.
Isenolic 8% formulation showed dose-dependent anti-influenza activity with IC50 of 65.5 µg/ml (vs 171.4 µg/ml for 4% formulation). Neuraminidase inhibition up to 64% (vs 88% for oseltamivir). Pre-treatment with 8% Isenolic at 100 µg/ml preserved 72.9% cell viability post-infection. These are in-vitro (cell-culture) findings only and do not demonstrate that Isenolic prevents or treats influenza in people; the results are hypothesis-generating for further human study.
Double-blind, randomized clinical study (Australian/New Zealand Clinical Trials Registry trial ID 378823). Maximum 4-month participant duration with two groups (active ingredient vs placebo). Isenolic standardized for ELA at 150 mg/capsule, 2 capsules/day (300 mg total) taken immediately upon symptom onset.
Healthy adults experiencing cold/flu symptom episodes. 2-week supply (28 capsules) per illness event.
Registered with formal trial protocol on the Australian New Zealand Clinical Trials Registry. Trial protocol evaluated symptom duration, severity, and frequency of respiratory illness events with Isenolic vs placebo over the 4-month study window. As of this writing this is a registered trial protocol only; no results have been published, so it does not yet provide evidence of efficacy.
Independent randomized controlled trial of olive leaf extract (containing 100 mg oleuropein equivalent, 20 g olive leaf) for upper respiratory illness (URI) in high school athletes during competitive season. 9-week intervention. Published in Nutrients (PMID 30744092).
32 high school students competing at elite sports level. 9-week intervention during competitive season.
No significant difference in URI incidence between olive leaf extract and placebo groups (OR 1.02, 95% CI 0.21-4.44). However, significant 28% reduction in sick days when supplemented with olive leaf extract (OR 0.72, 95% CI 0.56-0.93, p=0.02). Effect on duration/severity rather than incidence is consistent with the Isenolic positioning for symptomatic relief once illness has begun.